Opexa Therapeutics Inc news

   Watch this stock
Showing stories 1 - 10 of about 79   

Articles published

OPXA 0.810 -0.030 (-3.55%)
price chart
Opexa Therapeutics Inc (OPXA): 9 Compelling Reasons To Buy Opexa ...
Today my focus is on Opexa Therapeutics (NASDAQ:OPXA), a small-cap biotech principally focused on conquering Secondary Progressive Multiple Sclerosis (SPMS).
Related articles »  
Losing Stocks Under Consideration - Opexa Therapeutics, (NASDAQ:OPXA ...
Formerly on February 25, Opexa Therapeutics, Inc. (OPXA), a corporation developing personalized immunotherapies for autoimmune disorders, counting multiple sclerosis (MS) and neuromyelitis optica (NMO), declared that it has set 5:00 p.m.
Opexa Therapeutics, Inc. Announces Record Date and Subscription Price for ...
THE WOODLANDS, Texas - Opexa Therapeutics, Inc. (NASDAQ: OPXA), a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), today announced that it has set ...
Opexa Therapeutics, Inc. Files Registration Statement for Rights Offering
THE WOODLANDS, Texas, Jan 28, 2015 (BUSINESS WIRE) -- Opexa Therapeutics, Inc. OPXA, +10.36% a company developing personalized immunotherapies for autoimmune disorders, including multiple sclerosis (MS) and neuromyelitis optica (NMO), ...
Opexa Therapeutics, Inc. Price Target Update
Opexa Therapeutics, Inc. (NASDAQ:OPXA) stock has received a short term price target of $ 4 from 1 Analyst. The share price can be expected to fluctuate from the mean short term target, can be seen from the standard deviation reading of $0.
Update: Takeaways From Opexa's Plan To Dilute Shareholders (OPXA)
In April, I wrote a PRO article on Opexa Therapeutics (NASDAQ:OPXA) with a thesis stating that ongoing clinical success of Opexa's lead drug candidate, Tcelna (imilecleucel-T), could translate to regulatory approval and potentially fill a significantly ...
Opexa Therapeutics Inc Analyst Rating Update
Analysts at Zacks have given a Neutral rating on Opexa Therapeutics Inc (NASDAQ:OPXA) with a rating of 3. The counter has received an average rating of 1 from 2 brokerage firms.
Opexa Therapeutics Reports Year End 2014 Financial Results and Provides ...
THE WOODLANDS, Texas--(BUSINESS WIRE)--Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biopharmaceutical company developing personalized immunotherapies including multiple sclerosis (MS) and neuromyelitis optica (NMO), today reported financial ...
Opexa Therapeutics Annual Loss Narrows  RTT News
Stock Updates: Opexa Therapeutics Inc , Cempra Inc , Fiserv Inc
Opexa Therapeutics Inc (OPXA) faced minor selling declining 5.12% or 0.0448 points. The day began with the first trade at 0.88 and the counter witnessed wide fluctuations from thereon.
Opexa Therapeutics Poised For Breakout
The drop also ignored the potential of other technologies developed by the company. Short sellers received margin calls in August 2009;; when shares rose 450% in one day.